Harrow to Present at Two Investor Conferences in December

Harrow, Inc. (Nasdaq: HROW), a prominent provider of ophthalmic disease management solutions in North America, has announced its participation in two significant investor conferences scheduled for December 2025. The first event is the BTIG 5th Annual Ophthalmology Day, which will take place in a virtual format on Monday, December 1, 2025, at 8:30 AM EST. The second event is the Piper Sandler 37th Annual Healthcare Conference, set to be held in New York City on Tuesday, December 2, 2025, at 3:00 PM EST. Both presentations will feature a fireside chat format, providing a platform for management to discuss the company's strategies, innovations, and market position in the ophthalmic sector.

Notably, the fireside chat at the Piper Sandler conference will be accessible via a live webcast, allowing a broad audience to engage with the content. Following the live event, a replay will be available for approximately 90 days on the company’s website, ensuring that stakeholders and interested parties can revisit the discussions at their convenience.

Established with a mission to provide safe, effective, accessible, and affordable ophthalmic medications, Harrow offers a diverse range of products targeting various ocular conditions, including dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, and glaucoma. The company emphasizes enhancing patient compliance and improving clinical outcomes, which are critical to its operational ethos.

For additional information about Harrow and its participation in these upcoming conferences, interested parties are encouraged to visit the company's website or contact Mike Biega, the Vice President of Investor Relations and Communications.

Harrow (Nasdaq: HROW), a prominent player in the ophthalmic disease management sector, is poised for notable market engagement as it confirms its participation in two investor conferences this December—the BTIG 5th Annual Ophthalmology Day and the Piper Sandler 37th Annual Healthcare Conference. These events offer critical opportunities for Harrow to share insights about their innovative product portfolio and growth strategy with a broader investment community.

Given Harrow’s focus on a comprehensive range of eye care solutions, including treatments for dry eye disease and age-related macular degeneration, the upcoming presentations should highlight both their recent advancements and commitment to enhancing patient outcomes. Investors should focus on any announcements regarding pipeline developments or partnerships that may signal growth potential.

The market landscape for ophthalmic solutions continues to evolve, driven by an aging population and growing prevalence of eye-related conditions. Analysts may view Harrow’s participation in these conferences as a positive indication of the company's proactive approach to investor relations and transparent communication. The virtual format of the BTIG conference can facilitate broader participation while the Piper Sandler event provides a traditional, in-person setting for more direct engagement.

Harrow’s stock performance around the time of these conferences could reflect investor sentiment towards the company’s ability to effectively communicate its value proposition and growth strategy. Therefore, investors should consider monitoring the company's stock performance in the weeks leading to and following these events.

In conclusion, with a strategic focus on innovation in ophthalmic management and an active engagement in investor communications, Harrow appears well-positioned for continued growth. Analysts and investors should pay close attention to key messages from management during these conferences, as they have the potential to influence market perceptions and the stock’s trajectory.